Tag: Opdivo adjuvant therapy

Home / Opdivo adjuvant therapy

Categories

Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma

Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and ol...
opdivo-adjuvant-therapy

Scan the code